Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study GroupPeter Borchmann, Andreas Engert, Heinz Haverkamp et al.|Journal of Clinical Oncology|2011Cited by 190
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Loretta J. Nastoupil, Koji Izutsu et al.|Nature Medicine|2024Cited by 127
Idarubicin: a brief overview on pharmacology and clinical use.Peter Borchmann, Andreas Engert, Kai Hübel et al.|PubMed|1997Cited by 57
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphomaPeter Borchmann, Andreas Engert, R. Schnell et al.|Annals of Oncology|2001Cited by 52